Adgyl Lifesciences

Adgyl Lifesciences offers comprehensive range of in vivo services to support Discovery, Preclinical and Early to late stage development of novel molecules with non-clinical IND track and NDA enabling safety assessment studies for global regulatory registrations. With 30+ years of GLP experience, we ensure reliability and accuracy of data with the highest level of quality and customer satisfaction. With specialized facilities and a wealth of experience, we offer services for diverse industries - biotech, pharmaceuticals, biologics, medical devices, agrochemicals, cosmetics, nutraceuticals, animal health products, specialty chemicals and industrial chemicals. Our team has supported 90+ end-to-end IND enabling packages, 65+ Carcinogenicity...

Preclinical research,toxicology,drug development,drug discovery,ecotoxicology,genetic toxicology,dmpk,in vitro studies,in vivo studies,safety assessment,e-fate,medical device testing,and in vivo pharmacology

Adgyl lifesciences operates in the Research services industry.

Adgyl lifesciences's revenue is 11m - 100m

Adgyl lifesciences has 51 - 200 employees.